ABSCI announces pricing of $100M underwritten offering

Absci Corporation (Nasdaq: ABSI) has announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. The company has also granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares on the same terms and conditions. The gross proceeds from the offering are expected to be approximately $50 million, excluding any exercise of the underwriters' option to purchase additional shares.

Absci intends to use the net proceeds from the offering to fund the advancement of its internally developed programs, continued investment in its Integrated Drug Creation™ platform, and for working capital and other general corporate purposes.

Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are acting as joint book-running managers for the offering. The offering is expected to close on or about July 25, 2025, subject to the satisfaction of customary closing conditions.

The shares of common stock are being offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267043) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on August 24, 2022 and became effective on September 2, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on July 24, 2025.

This offering follows a series of public offerings and follow-on offerings by Absci and other biopharmaceutical companies, reflecting ongoing capital-raising activity in the sector.